PredicineBEACON™

Personalized, Actionable MRD Assay

Sensitive Molecular Residual Disease (MRD) detection not limited by baseline tissue sample availability

Tissue Optional

Baseline sample: tissue, blood, or urine

Personalized Tracking

Up to 250 patient-specific variants

Ultra-Sensitive

LoD95: 5 PPM
(with reportable range down to 0.1 ppm)*

Therapy Guidance

500 actionable hotspots

Assay Workflow

PredicineWES+ or WGS:

Baseline or EOT Profiling

PredicineBEACON:

MRD Monitoring



- PredicineWES+ or WGS (tissue, blood, or urine)
- LP-WGS for tumor fraction (optional, blood/urine)

Germline & CHIP Variant Filtering

- Up to 250 personalized variants (down to 4)
- 500 actionable variants
- LP-WGS (optional)

Assay Specifications

	Baseline or EOT Profiling	MRD Monitoring
Specimen Type and Requirement	Blood: 10 mL Plasma: 2-5 mL Urine: 25-40 mL Tissue: ≥ 1mm^3 tissue (5-10 FFPE slides)	Blood: 20 mL Urine: 25-40 mL
Turnaround Time (TAT)	20 business days	6 business days
Alterations Tested by MRD	Mutations, SVs, CNVs (optional)	
MRD sensitivity (60 ng)*	Reportable range down to 0.1 ppm	
Longitudinal TF (30 ng)*	Down to 0.005%	

Note: some features are only included in the RUO version. Additional information available upon request.

Predicine, Inc. | +1 (650) 300-2188 | contact@predicine.com | www.predicine.com

@predicine


@predicine

PredicineBEACON™

Personalized, Actionable MRD Assay

Tissue-informed MRD is prognostic in HNSCC


MRD positivity detected by PredicineBEACON correlated with shorter overall survival (HR=18.93) and a median lead time of 5 months before clinical recurrence.



Ruiz-Torres DA, et al. JAMA Otolaryngology-Head & Neck Surg. 2026

Urine-informed MRD guides bladder-sparing in MIBC

PredicineBEACON urine MRD testing guides adaptive selection of bladder preservation or radical cystectomy during neoadjuvant therapy for MIBC.



Zhang R, et al. Clinical Cancer Research, 2023

© 2026 Predicine, Inc. All rights reserved. All trademarks are the property of Predicine, Inc. or their respective owners.

For Research Use Only. Not for use in diagnostic procedures.

Predicine, Inc. | +1 (650) 300-2188 | contact@predicine.com | www.predicine.com

@predicine


@predicine

PredicineBEACON™


Personalized, Actionable MRD Assay


Bidirectional insights inform early go/no-go decisions

PredicineBEACON bidirectional design integrates baseline/EOT profiles with on-treatment MRD/resistance tracking to capture real-time evolution, inform early go/no-go decisions, and accelerate drug development.



Bidirectional blood-informed MRD predicts clinical outcomes and monitors resistance*





* References:
Sacher A, et al. N Engl J Med,2023
Desai J, et al. Nature Medicine, 2023
Choi Y, et al. Clinical Cancer Research, 2024

Learn more at
Publications-Predicine

© 2026 Predicine, Inc. All rights reserved. All trademarks are the property of Predicine, Inc. or their respective owners.
For Research Use Only. Not for use in diagnostic procedures.

Predicine, Inc. | +1 (650) 300-2188 | contact@predicine.com | www.predicine.com
@predicine
@predicine